1:43 PM Jan 18, 2019

ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data...

1:22 PM Jan 18, 2019

Pharma falling off budget cliff

Three strong arms are lining up in Washington to take turns whacking the biopharma piñata. Divisions within the industry, a lack of new ideas, and resistance to change are making a bad situation...

7:40 PM Jan 17, 2019

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address.

6:20 PM Jan 17, 2019

Exploring 3-D genomic white space

Gene regulation is offering a new class of targets that operate on a higher level than DNA sequences and epigenetic markers: 3-D genomic structures. While strategies to drug the 3-D genome are...

5:03 PM Jan 11, 2019

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality.

1
2
3
4
5

Latest News

4:30 PM Jan 18, 2019

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late...

3:39 PM Jan 18, 2019

AbbVie's Imbruvica misses pancreatic cancer endpoints

AbbVie Inc. (NYSE:ABBV) said late Friday Imbruvica ibrutinib missed the co-primary endpoints in the Phase...

3:38 PM Jan 18, 2019

Winners of China's centralized procurement to secure over 60% market share

Companies that won tender bids for China's pilot program for centralized procurement of generic drugs will...

3:00 PM Jan 18, 2019

Grassley squeezes government on foreign IP theft

Sen. Chuck Grassley (R-Iowa) suggested that the federal government is not taking sufficient steps to...

12:38 PM Jan 18, 2019

Agency moves to tamp down on coupons in exchange plans

In a proposed payment notice for plan year 2020, CMS has taken a page from commercial plan sponsors by...

12:17 PM Jan 18, 2019

CMS aims to spread risk of catastrophic coverage

On Friday, CMS unveiled the Medicare Part D Payment Modernization model that seeks to share the costs of...

6:04 AM Jan 18, 2019

FDA delays approval of Immunomedics' ADC for triple-negative breast cancer

Immunomedics Inc. (NASDAQ:IMMU) said FDA issued a complete response letter for its BLA for sacituzumab...

5:43 AM Jan 18, 2019

Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said it will suspend promotion of Lartruvo olaratumab after it missed the...

4:35 PM Jan 17, 2019

ICER to probe for clinical justification of drug price hikes

The Institute for Clinical and Economic Review unveiled more details on its plans to evaluate whether...

4:31 PM Jan 17, 2019

BIO, NVCA urge U.S. to ensure export controls won't hinder innovation

BIO has asked the U.S. Department of Commerce to consider the full impact export controls would have on...

4:08 PM Jan 17, 2019

Novartis to scale up data science under AI deal with Oxford

Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Oxford's Big Data Institute (BDI) will use...

3:51 PM Jan 17, 2019

Gilead, Genentech join PhRMA

PhRMA President and CEO Stephen Ubl announced Thursday that Genentech Inc. and Gilead Sciences Inc. (...

3:28 PM Jan 17, 2019

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to...

3:21 PM Jan 17, 2019

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator...

3:17 PM Jan 17, 2019

Management tracks: eGenesis names Sekhri CEO

Xenotransplantation company eGenesis Inc. (Cambridge, Mass.) hired Paul Sekhri as president and CEO. He...

1:45 PM Jan 17, 2019

Mirati, Revance price follow-ons

Mirati Therapeutics Inc. (NASDAQ:MRTX) and Revance Therapeutics Inc. (NASDAQ:RVNC) have each raised $100...

1:04 PM Jan 17, 2019

NIH to bring iPS cell therapy into clinic for dry macular degeneration

Researchers at NIH's National Eye Institute (NEI) developed clinical-grade protocols for producing an...

7:46 AM Jan 17, 2019

FDA removes a barrier to OTC naloxone development

To make it easier for drug manufacturers to develop over-the-counter naloxone, FDA released Thursday two...

4:53 PM Jan 16, 2019

Phoenix, Roche partner to develop TNBC biomarker

Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Wednesday to...

3:59 PM Jan 16, 2019

Juvenescence raises first tranche of $100M series B

Juvenescence Ltd. (Douglas, Isle of Man) raised $46 million in the first tranche of a $100 million series...

Down Up